

The Case for Tailored Prostate Cancer Screening: An NCCN Perspective

Michelle L. McDonald, MD, and J. Kellogg Parsons, MD, MHS

Abstract

A preponderance of clinical evidence supports a significant public health benefit for screening and early detection of prostate cancer in selected men. The challenge lies in maximizing early diagnosis of potentially aggressive but curable disease while minimizing diagnosis and treatment of indolent disease. A tailored approach to population screening in appropriately counseled men, using an evidence-based strategy with judicious prostate-specific antigen (PSA) testing, will reduce prostate-cancer mortality yet limit overdiagnosis of clinically insignificant disease. Use of newer biomarkers that increase specificity for prostate cancer detection, including percentage of free PSA, 4Kscore, prostate health index, prostate cancer antigen 3, and multiparametric MRI may be considered under certain circumstances. (*J Natl Compr Canc Netw* 2015;13:1576–1583)

NCCN: Continuing Education

Accreditation Statement

This activity has been designed to meet the educational needs of physicians and nurses involved in the management of patients with cancer. There is no fee for this article. No commercial support was received for this article. The National Comprehensive Cancer Network (NCCN) is accredited by the ACCME to provide continuing medical education for physicians.

NCCN designates this journal-based CME activity for a maximum of 1.0 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

NCCN designates the education activity for a maximum of 1.0 contact hour. Accreditation as a provider refers to recognition of edu-

cational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

All clinicians completing this activity will be issued a certificate of participation. To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 66% minimum passing score and complete the evaluation at <http://education.nccn.org/node/77390>; and 4) view/print certificate.

Release date: December 21, 2015; Expiration date: December 21, 2016

Learning Objectives

Upon completion of this activity, participants will be able to:

- Describe the rationale for tailoring prostate cancer early detection toward younger populations
- Explain how biomarkers and imaging studies might improve the specificity of prostate cancer detection

From the Department of Urology, UC San Diego Health System, La Jolla, California.

Submitted June 21, 2015; accepted for publication October 15, 2015.

Dr. McDonald has disclosed that she has no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. Dr. Parsons has disclosed that he receives consulting fees and honoraria from MDxHealth.

Correspondence: J. Kellogg Parsons, MD, MHS, Department of Urology, UC San Diego Health System, 3855 Health Sciences Drive #0987, La Jolla, CA 92093-0987. E-mail: k0parsons@mail.ucsd.edu

EDITOR

Kerrin M. Green, MA, Assistant Managing Editor, *JNCCN—Journal of the National Comprehensive Cancer Network*

Ms. Green has disclosed that she has no relevant financial relationships.

CE AUTHORS

Deborah J. Moonan, RN, BSN, Director, Continuing Education, has disclosed that she has no relevant financial relationships.

Ann Gianola, MA, Manager, Continuing Education Accreditation & Program Operations, has disclosed that she has no relevant financial relationships.

Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, has disclosed that she has no relevant financial relationships.

Rashmi Kumar, PhD, Senior Manager, Clinical Content, has disclosed that she has no relevant financial relationships.

Deborah A. Freedman-Cass, PhD, Oncology Scientist/Senior Medical Writer, has disclosed that she has no relevant financial relationships.

Overview

Prostate cancer remains the most commonly diagnosed noncutaneous cancer and the second leading cause of cancer death among men in the United States. In 2015, approximately 220,800 men will be diagnosed with and 27,540 will die of prostate cancer.¹ Since the early 1990s,¹ prostate cancer mortality has decreased 45%. Although potentially due in part to lead time bias after earlier detection through widespread use of prostate-specific antigen (PSA) testing, this trend has also largely been attributed to the treatment of screen-detected tumors.²⁻⁴ Randomized trials have since confirmed the efficacy of PSA population screening to diminish prostate cancer mortality (Table 1).

Nevertheless, aggressive screening, diagnosis, and treatment of prostate cancer has generated debate regarding overdiagnosis.⁵ Overdiagnosis is the diagnosis of screen-detected indolent prostate cancer that, left untreated, would otherwise not provoke symptoms or diminish overall or prostate cancer-specific survival. Overtreatment of screen-detected indolent cancers with surgery and radiation may expose patients to substantial risks of urinary incontinence, erectile dysfunction, and proctitis.

The NCCN Prostate Cancer Early Detection Guidelines Panel recognizes that not all men diagnosed with prostate cancer require treatment. They acknowledge that maximizing the early detection of prostate cancer will increase the detection of both indolent and aggressive cancers among informed men who have elected to participate in a screening program.⁶ To decrease prostate cancer mortality, yet mitigate against the potential morbidities of overdiagnosis and overtreatment, the panel has recommended a tailored approach to prostate cancer screening emphasizing judicious application of evidence-based principles.⁶

Weighing the Evidence: Population-Based PSA Screening Trials

In 2012, the US Preventive Services Task Force (USPSTF) concluded from the available evidence that the potential harms of PSA testing outweigh its potential benefits, and issued a “D” grade for PSA testing, recommending against population-based screening for prostate cancer.⁷

However, results of 2 of 3 randomized controlled trials of PSA screening—the European Randomized Study of Screening for Prostate Cancer (ERSPC)⁸

and the Göteborg screening trial⁹—suggested a substantial public health benefit to screening in the form of reduced prostate cancer mortality. Moreover, although the third trial, the prostate arm of the US Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, showed no benefit to screening, the PLCO could not assess the benefit of PSA-based screening on prostate cancer mortality because of excessive screening in the control arm.

The ERSPC, initiated in 1991 among 7 different European countries, randomized 162,388 men aged 55 to 69 years to a screening or control arm.⁸ Men were screened every 2 to 4 years with a PSA test. After 13 years of follow-up, the rate ratio of prostate cancer mortality in the screened arm was 21% (95% CI, 0.69–0.91), equivalent to 1 prostate cancer death averted per 781 men screened, or 1 per 27 additional prostate cancers detected.¹⁰ Potential shortcomings of the ERSPC include lack of a significant effect of screening on all-cause mortality, overreliance on secondary analyses adjusting for noncompliance, and unbalanced treatment differences between study arms.^{11,12}

The Göteborg screening trial randomized 20,000 men aged 50 to 64 years to biannual PSA-based screening or a control condition until age 69 years.⁹ At a median follow-up of 14 years, a 44% risk reduction in prostate cancer-related deaths was seen in the screening arm. Notably, half of the prostate cancers detected in the screening arm were not immediately treated, suggesting a survival benefit even when early detection is combined with selective treatment.

The PLCO trial was performed in 10 centers across the United States from 1993 to 2001.^{13,14} A total of 76,685 men aged 55 to 74 years were randomized to screening or usual care (control arm). Screened men were offered an annual PSA test for 6 years and a digital rectal examination (DRE) for 4 years. Although no difference in prostate cancer mortality was seen between the groups at a median follow-up 13 years, there was significant noncompliance in the control arm, with a compliance rate of 52% per year versus 85% in the screening arm; 74% of men in the control arm were screened at least once. Poor compliance in the control arm would have driven differences between the arms toward the null. In addition, the PLCO trial also had very low biopsy rates among men with elevated PSA levels: 40% in the first year and 30% by the third year.¹⁵ Thus, the PLCO arm could not effectively test

McDonald and Parsons

Table 1 Randomized Controlled PSA-Based Screening Trials and Subanalyses

Study, Year	Study Population	Study Sample	Intervention	Median Length of Follow-Up, y	PCa Death Reduction	Limitations	Comments
ERSPC, ^{8,10} 2009	7 European countries 1991–2003	162,388 men aged 55–69 y	Randomized to PSA screening every 2–4 y or control	9	Yes RRR=20% NNT=48	Median age of men was >60 y Long screening interval (largely q4y) Inconsistencies in screening interval and biopsy threshold	NNT assumes all men diagnosed are treated, therefore was rephrased in subsequent reports
			Prostate biopsy most often when PSA level >3 ng/mL	11	Yes RRR=21% NND=37		
				13	Yes RRR=21% NND=27		
Göteborg, ⁹ 2010	Goteborg, Sweden, 1944	20,000 men aged 50–64 y	Randomized to biannual PSA screening or control until age 69 y Prostate biopsy when PSA level >2.5–3.0 ng/mL	14	Yes RRR=44% NND=12	60% of men born between 1930–1939 previously included in overall ERSPC results	Half of the men with PCa detected in screened arm were not immediately treated Contamination rate estimated at 3% Not independent from larger ERSPC trial
Rotterdam, ^{59,60} 2014	Rotterdam, Netherlands, 1993–2010	34,833 men aged 55–69 y	Randomized to PSA screening q4y until age 75 y Biopsy when PSA level ≥3–4 ng/mL	13	Yes RRR=32% When corrected for nonattendance and contamination, RRR=51%	Extrapolation of PSA contamination data Use of questionnaire to assess reason for PSA testing in those without PCa	
PLCO, ^{13,14} 2009	10 US centers, 1993–2001	76,685 men aged 55–74 y	Randomized to screening with annual PSA testing for 6 y & DRE for 4 y or usual care (control) Biopsy when PSA level ≥4 ng/mL	13	No	Significant noncompliance in control arm: 74% were screened at least once Low biopsy rates in men with elevated PSA levels	Not a trial of screening vs no screening, but rather annual screening vs ad hoc screening
Leob et al, ²³ 2011	10 US centers, 1993–2001	73,378 men aged 55–75 y who filled out comorbidity questionnaire before study entry	See PLCO	10	Yes, when results analyzed by comorbidity status, RRR=44%	Possible methodological errors in analysis	Suggests screening is more useful among men in good health

Abbreviations: ERSPC, European Randomized Study of Screening for Prostate Cancer; DRE, digital rectal examination; NNT, number needed to detect; NNT, number needed to treat; PCa, prostate cancer; PLCO, Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; PSA, prostate-specific antigen; RRR, relative risk reduction.

whether a screening intervention reduced prostate cancer mortality compared with a control condition.

Collectively, the level I evidence from these trials—2 observing robust overall benefits, 1 suggesting a significant benefit in a subgroup analysis—supports PSA screening to reduce prostate cancer mortality.

Shifting the Screening Strategy

The 2 extremes of a PSA-screening strategy—pursuit of unrefined, unconstrained PSA testing versus blanket cessation of all testing—both fail to acknowledge the biologic heterogeneity of prostate cancer.¹⁶ Screen-detected prostate cancers constitute a spectrum of disease,

ranging from indolent (most of the cases diagnosed) to highly aggressive (which usually merit treatment with surgery or radiation even in older patients).¹⁷

Charting an even-handed, evidence-based path between the 2 extremes involves tailoring early detection efforts toward screening of younger populations and developing more stringent biopsy criteria.

Informed and Shared Decision-Making

Screening should be offered only to informed patients who have agreed to participate in an early detection program. Shared decision-making is a process in which physicians and patients collaborate to make decisions. The process requires informed patients.¹⁸ The responsibility of the physician is to help the patient understand the nature of the decision by providing evidence-based data and streamlined information.^{19,20} Patients should be counseled that the purpose of screening is to detect aggressive prostate cancers that are potentially curable, but they should also be advised that, in the process of detecting these cancers, indolent cancers may also be identified.¹⁹ Men should be counseled that the detection of indolent cancer does not equate to treatment, or at least immediate treatment, and that management must be individualized.^{19,21} The discussion should also include the potential direct harms of screening,¹⁸ which include false-positive PSA tests, potential additional unnecessary tests (ie, prostate biopsy), anxiety, diminished quality of life, risks of prostate biopsy, and risks of treatment.²²⁻²⁴

Risk Factors and Life Expectancy

Older age, African American race, and family history of prostate cancer are associated with increased risk of prostate cancer diagnosis and death. No PSA-based screening trial to date, or subgroup model of a screening trial, has definitively assessed the potential benefits of differential screening in higher-risk populations, and no population-based data demonstrate that selective screening of African Americans or men with a family history leads to improved cancer-specific or overall survival. PSA value is a stronger predictor for prostate cancer than race or positive family history.²⁵ Therefore, although these risk factors may be considered in the decision to participate in screening, the intensity of screening, and/or in the

interpretation of screening test results, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection do not offer separate screening recommendations for African Americans or positive family history.⁶

The prevalence of overdiagnosis depends in large part on life expectancy at the time of diagnosis. Men with limited life expectancies secondary to comorbid conditions and/or advanced age are the least likely to benefit from screening.^{26,27} Life expectancy estimation is therefore an important consideration in the decision to participate in screening. PSA testing should therefore only be offered to men with a 10-or-more-year life expectancy. Physicians tend to overestimate life expectancy and underestimate comorbidity²⁸; resources such as the Social Security Administration tables for life expectancy estimation may aid in decision-making.²⁹

Digital Rectal Examination

The role of DRE as a diagnostic tool for prostate cancer is uncertain in the modern era. DRE has poor sensitivity, limited specificity, and high interobserver variability.^{30,31} In the Prostate Cancer Prevention Trial, Thompson et al³² concluded that DRE added little value to screening, with an absolute difference of only 0.02 in the area under the curve for detecting prostate cancer compared with PSA alone.

On the other hand, men in the ERSPC with a serum PSA level greater than 3 ng/mL and abnormal DRE findings were more likely to be diagnosed with prostate cancer than those with a PSA level greater than 3 ng/mL alone.³³ DRE potentially may also help identify aggressive cancers in patients with lower (<2.5 ng/mL) PSA values.³⁴

Therefore, although DRE should not be used as a stand-alone screening test, it should be performed in men with an elevated PSA level, and may be considered as a baseline test in all men undergoing PSA screening, because it may potentially identify higher-risk cancer in men with lower PSA values.⁶

Age at Which to Initiate PSA Testing

The ERSPC and Göteborg trials observed a reduction in prostate cancer mortality in men who initiated screening at age 50 to 55 years, with the strongest evidence supporting testing beginning at

McDonald and Parsons

age 55 years. One hypothesis for the more robust mortality improvements observed in the Göteborg compared with the ERSPC trials were the median ages at study entry: 56 and 60 years, respectively. Despite these data, only 24% of men between the ages of 50 and 54 years are typically screened in the United States, and screening rates peak in men aged 70 to 74 years.³⁵

Data suggest that screening men aged 40 to 49 years confers only modest improvements in 10-year prostate cancer mortality.³⁶ However, some observational data suggest that there may be utility in testing men aged 40 to 55 years to aid in future risk stratification. A cohort study of Swedish men determined that a baseline PSA in early mid-life (45–55 years) identifies men at risk for metastases several decades later.³⁷

Based on these data, particularly the Göteborg study, it is reasonable to target a younger population of healthy men for PSA screening, with an age for screening initiation of 45 years.

Age at Which to Discontinue PSA Testing

Determining the age at which to discontinue screening in men with previously normal PSA values is a contentious issue. Approximately 50% of all prostate cancer screening occurs in older men (70–79 years), suggesting that most overdetection occurs in older men who are the least likely to develop clinically significant disease during their lifespan.³⁵ The ERSPC observed no benefit to screening men beyond age 70 years, whereas another study using prostate cancer microsimulation models predicted that decreasing the screening termination age from 74 years to 69 years would lead to a 50% reduction in the probability of overdetection.³⁸ The same study also assessed screening up to age 74 years while simultaneously increasing the PSA threshold for biopsy with increasing age, and determined that this strategy reduced overdiagnosis by one-third. Still, data from a surgical cohort of more than 4,500 men from the PSA screening era suggested that, compared with younger men, men older than 70 years had a significantly higher risk of adverse pathology and similar risks of biochemical recurrence, metastases, and prostate cancer–specific death.³⁹

The NCCN Prostate Cancer Early Detection Panel acknowledges the difficulty in identifying a stopping age for screening, and that its panelists

did not agree on this issue. At this time, the panel recommends screening up to age 75 years, with consideration given to offering screening to extremely healthy men older than 75 years using tools such as the Social Security Administration actuarial tables for life expectancy (category 2B recommendation).²⁹

Tailored Screening Frequency

Previous evidence-based guidelines have recommended annual screening.^{40–42} However, there are now data from randomized controlled trials to suggest that annual screening provides no additional survival benefit compared with screening at 2-year intervals. The NCCN Prostate Cancer Early Detection Panel acknowledges the difficulty in identifying a suitable interval for screening. However, although there is limited consensus, screening intervals may be tailored to PSA and age, with longer intervals used for younger men with lower PSA levels, because PSA value predicts future risk of clinically significant disease in younger men.⁴³

Age 45 to 75 Years

In men with a PSA level of less than 1 ng/mL who have elected to undergo screening, PSA testing should be performed at 2- to 4-year intervals; for those with a PSA level of 1.0 ng/mL or greater and less than 3.0 ng/mL, testing should be performed at 1- to 2-year intervals.^{40,43–46} For this age group, a PSA level greater than 1.0 ng/mL corresponds with the greater than 75th percentile for the population and is associated with increased risks of incident cancer and incident clinically significant cancer.⁴⁴

Age Older Than 75 Years

In this age group, screening may potentially be offered to very healthy men with a relatively high likelihood of clinically significant cancer, because the potential for overdetection is high and very few men will benefit.^{9,14,38,47}

Considerations for Biopsy

Prostate biopsy may be considered for those men with a PSA level greater than 3.0 ng/mL with or without abnormal DRE results.⁴⁰ In men older than 75 years, consideration may be given to increasing the PSA threshold to greater than 4 ng/mL.^{38,48} Otherwise, age-adjusted PSA cut points are not routinely recommended. Transrectal ultrasound-guided biopsy should

The Case for Tailored Screening

be performed in an extended pattern with a minimum of 12 cores obtained—sextant (6) and lateral peripheral zone (6)—that should incorporate palpable nodules and/or suspicious ultrasound images. Anteriorly directed biopsy is not recommended for a routine initial biopsy, but may be considered in the setting of a repeat biopsy. Other approaches that may be considered, particularly for repeat biopsy, include saturation techniques and transperineal templates.⁶

Biomarkers

Although currently not indicated as first-line screening tests, for patients and physicians who wish to further define the probability of biopsy-detectable cancer,

consideration may be given to newer biomarker tests that increase the specificity of prostate cancer detection, including percent free PSA (%free PSA),⁴⁹ the prostate health index (PHI),⁵⁰ prostate cancer antigen 3 (PCA3),⁵¹ and the 4-kallikrein (4Kscore) panel (Table 2).⁵² These tests may inform the decision to perform biopsy as a result of improved specificity for the detection of clinically significant prostate cancer compared with total PSA. The PHI incorporates the [-2] isoform of proPSA into the formula $PHI = ([-2] \text{ proPSA} / \text{freePSA}) \times \sqrt{\text{PSA}}$ and, in a multicenter study, was noted to have double the sensitivity of total or free PSA for cancer detection in men with a PSA level between 2 and 10 ng/dL.⁵³ The 4Kscore panel includes total PSA, free PSA,

Table 2 Additional Tests for the Early Detection of PCa in Setting of Elevated PSA

	Test Name	Sample	Year of FDA Approval	Measures	Comments
No prior biopsy	phi	Blood	2012	Variants of PSA $PHI = ([-2] \text{ proPSA} / \text{freePSA}) \times \sqrt{\text{PSA}}$	Recommended in men with PSA level between 3 and 10 ng/mL PHI >35 suspicious for PCa
	4Kscore panel	Blood	N/A	4 kallikrein markers: total PSA, free PSA, intact PSA, hK2	Provides a probability score, 0%–100%, of clinically significant PCa on biopsy
Negative prior biopsy	phi	Blood	2012	Variants of PSA $PHI = ([-2] \text{ proPSA} / \text{freePSA}) \times \sqrt{\text{PSA}}$	Recommended in men with PSA level between 3 and 10 ng/mL PHI >35 suspicious for PCa
	4Kscore panel	Blood	N/A	4 kallikrein markers: total PSA, free PSA, intact PSA, hK2	Provides a probability score, 0%–100%, of clinically significant PCa on biopsy
	%free PSA	Blood	1998	Unbound PSA as a ratio of total PSA	Recommended in men with PSA level between 4 and 10 ng/mL %free PSA <10% suspicious for PCa
	PCA3	Urine	2012	Prostate tissue-specific RNA	Approved in setting of negative biopsy in men aged >50 y PCA3 level >35 suspicious for PCa
	MRI	N/A	N/A	Scoring systems for suspicion of identified lesions ^a	Suspicious lesions can be used as targets for biopsy
	Confirm-MDX ^b	Prostate biopsy tissue	N/A	Measures epigenetic field effect from hypermethylation of DNA	Predicts probability of undiagnosed cancer

Abbreviations: 4Kscore, 4-kallikrein; %free PSA, percentage of free prostate-specific antigen; $\sqrt{\text{PSA}}$, square root of prostate specific antigen; hK2, human kallikrein 2; N/A, not applicable; PCa, prostate cancer; PCA3, prostate cancer antigen 3; phi, prostate health index; PIRADS, prostate imaging reporting and data system; proPSA, pro-prostate specific antigen; PSA, prostate-specific antigen.

^aThe PIRADS system is based on probability of clinically significant cancer and ranges from PIRADS 1 (ie, very low, clinically significant cancer is highly unlikely to be present) to PIRADS 5 (ie, very high, clinically significant cancer is highly likely to be present)

^bThe NCCN Prostate Cancer Early Detection Panel has not issued evidence-based recommendations regarding this assay.

McDonald and Parsons

intact PSA, and human kallikrein 2 (hK2); several studies have confirmed its accuracy in the detection of clinically significant cancer (Gleason score ≥ 7) and its potential to reduce the number of unnecessary biopsies.^{52,54}

The PHI and 4Kscore⁵⁴ tests are potentially informative during initial screening in men who have never undergone biopsy; PHI, 4Kscore, %free PSA, and urinary PCA3 are robust in selecting for repeat biopsy in those patients who have undergone at least one prior negative biopsy.^{51,55}

MRI

Increasing interest is being shown in the role of multiparametric MRI in prostate cancer diagnosis. Recent evidence suggests a benefit of MRI-targeted prostate biopsy compared with standard transrectal ultrasound-guided biopsy in the detection of clinically significant cancer.⁵⁶ However, to date no definitive data show that MRI informs the decision to perform an initial prostate biopsy. Therefore, with respect to prostate cancer diagnosis, consideration of MRI is currently recommended only in patients with a prior negative biopsy.⁶

Tissue Assays

At least one commercial assay exists that uses tissue from a prior negative biopsy to predict the probability of prostate cancer diagnosis on repeat biopsy. This assay measures an epigenetic field effect based on DNA hypermethylation in paraffin-embedded tissue.^{57,58} The NCCN Prostate Cancer Early Detection Panel does not recommend its use at this time, and it remains unclear whether this assay informs the decision to perform repeat biopsy after a prior negative biopsy in the context of other available biomarkers (ie, PHI, 4Kscore, %free PSA, and PCA3).⁶

Conclusions

Level 1 evidence indicates that prostate cancer screening reduces prostate cancer-specific mortality. A judicious, tailored approach to population screening using PSA testing every 1 to 4 years in appropriately counseled men ages 50 to 75 years would substantially reduce prostate cancer mortality, yet limit over-detection of clinically insignificant disease. Although prostate biopsy may be considered in appropriately selected patients with PSA levels less than 3 ng/mL, newer biomarkers, including 4Kscore, PHI, %free PSA, and urinary PCA3, and multiparametric prostate MRI, may improve specificity for prostate cancer

detection and thus inform the decision to perform prostate biopsy.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin* 2015;65:5–29.
2. Jhaveri FM, Klein EA, Kupelian PA, et al. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. *J Clin Oncol* 1999;17:3167–3172.
3. Etzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. *Cancer* 2012;118:5955–5963.
4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013;63:11–30.
5. Carroll PR, Vickers AJ. Point/Counterpoint: early detection of prostate cancer: do the benefits outweigh the consequences? *J Natl Compr Canc Netw* 2014;12:768–771.
6. Carroll PR, Parsons JK, Andriole G, et al. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. *J Natl Compr Canc Netw* 2014;12:1211–1219; quiz 1219.
7. Moyer VA; on behalf of the U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2012;157:120–134.
8. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med* 2009;360:1320–1328.
9. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. *Lancet Oncol* 2010;11:725–732.
10. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. *Lancet* 2014;384:2027–2035.
11. Thompson IM, Tangen CM. Prostate cancer screening comes of age. *Lancet* 2014;384:2004–6.
12. Ilic D, Dahm P. Prostate cancer screening in Europe. *Lancet* 2015;385:1506.
13. Andriole GL, Crawford ED, Grubb RL III et al. Mortality results from a randomized prostate-cancer screening trial. *N Engl J Med* 2009;360:1310–1319.
14. Andriole GL, Crawford ED, Grubb RL III, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. *J Natl Cancer Inst* 2012;104:125–132.
15. Grubb RL III, Pinsky PF, Greenlee RT, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. *BJU Int* 2008;102:1524–1530.
16. Esserman L, Thompson I. Solving the overdiagnosis dilemma. *J Natl Cancer Inst* 2010;102:582–583.
17. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. *N Engl J Med* 2012;367:203–213.
18. Braddock CH 3rd, Edwards KA, Hasenberg NM, et al. Informed decision making in outpatient practice: time to get back to basics. *JAMA* 1999;282:2313–2320.
19. Vickers AJ, Edwards K, Cooperberg MR, Mushlin AI. A simple schema for informed decision making about prostate cancer screening. *Ann Intern Med* 2014;161:441–442.
20. Hoffman RM, Helitzer DL. Moving towards shared decision making in prostate cancer screening. *J Gen Intern Med* 2007;22:1056–1057.
21. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. *J Clin Oncol* 2011;29:3669–3676.
22. Heijnsdijk EA, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. *N Engl J Med* 2012;367:595–605.
23. Loeb S, Carter HB, Berndt SI, et al. Complications after prostate biopsy: data from SEER-Medicare. *J Urol* 2011;186:1830–1834.
24. Macefield RC, Metcalfe C, Lane JA, et al. Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. *Br J Cancer* 2010;102:1335–1340.
25. Vertosick EA, Poon BY, Vickers AJ. Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening. *J Urol* 2014;192:724–728.
26. Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. *JAMA* 2006;296:2336–2342.
27. Crawford ED, Grubb R III, Black A, et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. *J Clin Oncol* 2011;29:355–361.
28. Daskivich TJ, Chamie K, Kwan L, et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. *Cancer* 2011;117:2058–2066.
29. Social Security Administration. Period Life Table. 2009. Available at: <http://www.ssa.gov/OACT/STATS/table4c6.html>. Accessed April 30, 2015.
30. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of

The Case for Tailored Screening

- prostate cancer: results of a multicenter clinical trial of 6,630 men. *J Urol* 1994;151:1283–1290.
31. Schroder FH, van der Maas P, Beemsterboer P, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. *J Natl Cancer Inst* 1998;90:1817–1823.
 32. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. *J Natl Cancer Inst* 2006;98:529–534.
 33. Gosselaar C, Roobol MJ, Roemeling S, Schroder FH. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. *Eur Urol* 2008;54:581–588.
 34. Hattangadi JA, Chen MH, D'Amico AV. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death. *BJU Int* 2012;110:1636–1641.
 35. Drazer MW, Huo D, Schonberg MA, et al. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. *J Clin Oncol* 2011;29:1736–1743.
 36. Howard K, Barratt A, Mann GJ, Patel MI. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices. *Arch Intern Med* 2009;169:1603–1610.
 37. Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40–55 and long term risk of metastasis: case-control study. *BMJ* 2013;346:f2023.
 38. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen—based prostate cancer screening strategies: model estimates of potential benefits and harms. *Ann Intern Med* 2013;158:145–153.
 39. Sun L, Caire AA, Robertson CN, et al. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. *J Urol* 2009;182:2242–2248.
 40. Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. *J Natl Compr Canc Netw* 2012;10:1081–1087.
 41. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. *CA Cancer J Clin* 2010;60:70–98.
 42. Carroll P, Coley C, McLeod D, et al. Prostate-specific antigen best practice policy—part II: prostate cancer staging and post-treatment follow-up. *Urology* 2001;57:225–229.
 43. Vickers AJ, Cronin AM, Bjork T, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. *BMJ* 2010;341:c4521.
 44. Capitanio U, Perrotte P, Zini L, et al. Population-based analysis of normal total PSA and percentage of free/total PSA values: results from screening cohort. *Urology* 2009;73:1323–1327.
 45. Chun FK, Hutterer GC, Perrotte P, et al. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. *BJU Int* 2007;100:37–41.
 46. Ulmert D, Cronin AM, Bjork T, et al. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. *BMC Med* 2008;6:6.
 47. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. *N Engl J Med* 2012;366:981–990.
 48. Schaeffer EM, Carter HB, Kettermann A, et al. Prostate specific antigen testing among the elderly—when to stop? *J Urol* 2009;181:1606–1614; discussion 1613–1614.
 49. Partin AW, Brawer MK, Subong EN, et al. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. *Prostate Cancer Prostatic Dis* 1998;1:197–203.
 50. Filella X, Gimenez N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. *Clin Chem Lab Med* 2013;51:729–739.
 51. Gittelman MC, Hertzman B, Bailen J, et al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. *J Urol* 2013;190:64–69.
 52. Vickers AJ, Gupta A, Savage CJ, et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. *Cancer Epidemiol Biomarkers Prev* 2011;20:255–261.
 53. Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. *J Urol* 2011;185:1650–1655.
 54. Parekh DJ, Punnen S, Sjoberg DD, et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. *Eur Urol* 2015;68:464–470.
 55. Bradley LA, Palomaki GE, Gutman S, et al. Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. *J Urol* 2013;190:389–398.
 56. Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. *JAMA* 2015;313:390–397.
 57. Partin AW, Van Neste L, Klein EA, et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. *J Urol* 2014;192:1081–1087.
 58. Stewart GD, Van Neste L, Delvenne P, et al. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. *J Urol* 2013;189:1110–1116.
 59. Roobol MJ, Kranse R, Bangma CH, et al; ERSPC Rotterdam Study Group. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. *Eur Urol* 2013;64:530–539.
 60. Bokhorst LP, Bangma CH, van Leenders GJ, et al. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. *Eur Urol* 2014;65:329–336.

Instructions for Completion

To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 66% minimum passing score and complete the evaluation at <http://education.nccn.org/node/77390>; and 4) view/print certificate. After reading the article, you should be able to answer the following multiple-

choice questions. Credit cannot be obtained for tests completed on paper. You must be a registered user on NCCN.org. If you are not registered on NCCN.org, click on “New Member? Sign up here” link on the left hand side of the Web site to register. Only one answer is correct for each question. Once you successfully answer all posttest questions you will be able to view and/or print your certificate. Software requirements: Internet

Posttest Questions

1. Shared decision-making will result in more informed patients. Which of the following should clinicians discuss with their patients before recommending a prostate cancer early detection program?
 - A. Risks of prostate biopsy
 - B. Risks of treatment
 - C. False-positive PSA tests
 - D. All of the above
 - E. Both B and C
2. True or False: PSA value is a stronger predictor for prostate can-

cer than race or positive family history.

3. For men between the ages of 45–75 years who have elected to undergo screening and with a PSA ≥ 1.0 ng/mL and <3.0 ng/mL, PSA testing should be performed at:
 - A. Yearly
 - B. 1 to 2 year intervals
 - C. 2 to 4 year intervals
 - D. There are no formal recommendations

